No annual revenue total was found in MAIA Biotechnology, Inc.'s SEC filings.
MAIA Biotechnology, Inc. (MAIA) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-22.40M
Operating cash flow (TTM)
$-22.57M
-43.1% vs year-ago TTM
Free cash flow
—
EPS
$-0.70
Dividend per share
None
Shares outstanding
60.67M
+105.1% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MAIA (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Chicago, IL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1878313
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
|---|---|
| Operating income | -$24.3M |
| Net income | -$22.4M |
| Diluted EPS | -$0.70 |
| Operating cash flow | -$18.8M |
| Total assets | $9.7M |
| Total liabilities | $7.3M |
| Stockholders' equity | $2.4M |
| Cash and investments | $0 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 6, 2026 | Oct 6, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 22, 2026 | May 21, 2026 |
| 8-K |
Current report
Agreement ended
|
May 14, 2026 | May 14, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Other events
|
Apr 16, 2026 | Apr 16, 2026 |
All 503 MAIA Biotechnology, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.